Loading …

Ascilion’s proprietary microneedle technology enables quick, reliable, and comfortable access to molecular biomarkers. Our dermal interstitial fluid (dISF) sampling platform can be tailored towards virtually any analytical or sensor technology used within products intended for spot measurement or wearables.
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more